Loading
GFH375 is an experimental small-molecule drug from Genfleet Therapeutics (Shanghai) in phase 3 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at KRAS.
GFH375 is a small-molecule drug developed by Genfleet Therapeutics (Shanghai). Its target is KRAS (the sponsor names KRAS G12D). The sponsor states: GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation, blocking KRAS-driven signalling and cancer cell growth. ClinicalTrials.gov describes the intervention as: The experimental group receives GFH375 monotherapy, QD, orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07262567 (Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer) and NCT07668752 (A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation), in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT06500676, plans to enrol 407 participants with primary completion expected 2028-07-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
GFH375 is an oral, highly selective, non-covalent small-molecule inhibitor targeting the KRAS G12D mutation, blocking KRAS-driven signalling and cancer cell growth. Connects to KRAS.
1.GFH375 slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GFH375" OR ABSTRACT:"GFH375") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GFH375, not a curated reading list.
Shares KRAS, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares KRAS, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares GenFleet Therapeutics and the tag pipeline.
Shares KRAS, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS, Pancreatic ductal adenocarcinoma and the tag pipeline.